Atezolizumab and bevacizumab have different mechanisms of action, where the former blocks PD1/PD‐L1 interaction, therefore, stimulating the T cell immune response to kill cancer cells36; the latter targets VEGF, leading to inhibition of neo‐vascularization.37 Here, PDCD1 is linked to cancer.